Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Powered by their REMaster technology platform, Remix identifies patterns in RNA processing and exploits them to alter the way genes are read from the genome, correcting dysregulation, or eliminating the gene message altogether, thereby addressing disease drivers at their origin. Remix is advancing novel small molecules to transform the treatment of various diseases.
| Headquarters | Cambridge, MA |
| Website | www.remixtx.com |
| Pipeline | Preclinical |
| @RemixThera |